Food Quarterly – Who Decides What’s For Dinner Tonight?

A smorgasbord of quarterly results and financing activities

November 29, 2021 Claude Camire Analyst Articles, eR Reports, Food, Food Quarterly, Industry Reports

Food Quarterly - list of companieseResearch is pleased to publish our first Industry report on the Food & Beverage Industry.

We review different companies that compose the industry: the trends, issues, challenges, and their strategies. For this first edition, we will just provide an overview of the key points. Our ultimate goal is to identify companies and products that may have a strategic advantage in competing in this transforming industry.

You can download our 12-page Industry Research Report by clicking on the following link: eR-Q3-2021-FoodQuarterly-2021-11-29_FINAL3

REPORT HIGHLIGHTS:

(1) Latest Financial Results Highlights

(2) Industry Groups Influencing the Industry Trends

  • We review different companies that compose the industry: the trends, issues, challenges, and their strategies.
  • For this first edition, we will just provide an overview of the key points.
  • Our ultimate goal is to identify companies and products that may have a strategic advantage in competing in this transforming industry.

(3) Recent Financings and Deals

(4) Industry Comps

Some companies mentioned in the report:

You can download our 12-page Industry Research Report by clicking on the following link: eR-Q3-2021-FoodQuarterly-2021-11-29_FINAL3

Other eResearch Food Industry Articles and Reports:

Notes: All numbers in CAD unless otherwise stated. The author of this report, and employees, consultants, and family of eResearch may own stock positions in companies mentioned in this article and may have been paid by a company mentioned in the article or research report. eResearch offers no representations or warranties that any of the information contained in this article is accurate or complete. Articles on eresearch.com are provided for general informational purposes only and do not constitute financial, investment, tax, legal, or accounting advice nor does it constitute an offer or solicitation to buy or sell any securities referred to. Individual circumstances and current events are critical to sound investment planning; anyone wishing to act on this information should consult with a financial advisor. The article may contain “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are based on the opinions and assumptions of the Company’s management as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein. Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Please read eResearch’s full disclaimer.

About Claude Camire 4 Articles
Claude Camiré has been involved in Biotech, Healthcare and Pharma industries for almost 40 years, completing over $1 billion in financings and M&A transactions, and participated in licensing of drugs for biopharma companies. For more than a decade, he worked as a corporate finance advisor and research analyst at Dundee Securities and Paradigm Capital, initiating coverage on over 30 Canadian companies. For three decades, he worked for companies such as Abbott Labs, Biochem Pharma, Prometic Life Sciences, and Sanofi.

Related Articles